ASX: EIQ RELEASE **29 April 2026**

Quarterly Activities Report: Strong US commercial traction, accelerated EchoSolv AS usage, expanded sales team and advancement of multi-condition platform strategy

- **Agreement with Mayo Clinic in preparation for potential clearance of EchoSolv HF – Agreement enables Mayo Clinic to resell and distribute EchoSolv HF post FDA clearance**
- **EchoSolv HF will be deployed via Mayo Clinic Platform – Solutions Studio Program, providing Mayo hospitals, health system network and 80+ external partner hospitals the ability to participate**
- **Post quarter end, EchoSolv AS deployed with Mount Sinai, a leading US health system in New York**
- **Mount Sinai Health System comprises seven hospitals, more than 400 outpatient practices and over 3,760 beds**
- **Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital is ranked first in New York and second in the US for Cardiology, Heart & Vascular Surgery in U.S. News & World Report's 2025–26 Best Hospitals rankings**
- **EchoSolv AS US commercial pipeline exceeds 50 active accounts across seven stages, with increasing progression into proposal and contract negotiation phases**
- **Three recently closed-won contracts provide early validation, supporting a scalable US expansion strategy across major hospital networks**
- **250+ high-volume echocardiography centres being actively targeted, with active engagement across 4 of 7 priority US regions**
- **EchoSolv AS usage up ~131% QoQ, with 9,220 echocardiograms processed in Q1 CY26, highlighting accelerating clinical adoption**
- **Flagship site Beth Israel operating at full capacity, demonstrating scalability in high-throughput clinical environments**
- **Beth Israel is a leading Harvard Medical Teaching Hospital in Boston that undertakes ~30,000 echocardiograms per annum**
- **Expanded US sales team in place with key appointments secured to cover major regional areas, led by existing US Head of Commercial, Mr Nick Lubbers**
- **Four-region sales coverage and dedicated implementation capability to support onboarding and retention established to underpin growth trajectory**
- **Strengthened clinical evidence base, including heart failure data submitted to leading cardiology journal and positive interim health economics results**
- **EchoSolv HF progressing through FDA 510(k) pathway, supporting expansion into a significantly larger addressable market**
- **Platform strategy advancing, with additional indications including pulmonary hypertension hypertrophic cardiomyopathy, mitral regurgitation and cardio-oncology in development**
- **Commercial readiness enhanced through 10 new patent filings across global jurisdictions and four new trademarks in key markets**
- **Potential near term strategic partnerships with key industry participants advanced to underpin accelerated commercial deployment and US commercial deployment opportunities**
- **Continued focus on disciplined cost management resulted in cash balance of $11.14m at quarter end (31 December 2025: $13.21m) with R&D Tax Incentive of ~$0.8m pending**
- **Provides excellent financial flexibility for near term commercialisation of EchoSolv HF in the US, which has the potential to unlock significant revenue upside**

Sydney: AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) ("Echo IQ" or "the Company") is pleased to provide the following update on activities undertaken during the three-month period ended 31 March 2026 (the "quarter"), which highlight ongoing progress made across the Company's rollout of EchoSolv AS in the US, as well as product development initiatives, expansion of Echo IQ's sales team and strengthened intellectual property positioning.

Management commentary:

Chief Executive Officer, Mr Dustin Haines, said: *"During the March quarter, we have been focused on disciplined execution across all key pillars of our strategy, with strong progress in US commercialisation, accelerating platform utilisation and meaningful advancement of our multi-condition product roadmap. This has been underpinned by a distinct focus on capital management.*

From a US commercial perspective, we are achieving increasing depth and quality, with over 50 active accounts progressing through a structured, multi-stage process. Importantly, we are now advancing a number of institutions into later-stage engagement, including proposal and contract negotiation, which provides clear visibility on near-term conversion. Our focus on high-volume echocardiography centres continues to resonate, supporting a scalable 'land-and-expand' strategy across hospital networks and positioning us to capture enterprise-wide deployments.

Encouragingly, this commercial progress is translating into strong real-world utilisation. The step-change in EchoSolv AS usage, with over 130% quarter-on-quarter growth in echocardiograms processed, highlights increasing integration into clinical workflows and reinforces the platform's ability to operate at scale within leading institutions such as Beth Israel. We view this growth in utilisation as a leading indicator of future recurring, usage-based revenue and a critical driver of long-term value.

In parallel, we have continued to invest in the infrastructure required to support this growth. The expansion of our US-based sales and implementation team provides full regional coverage across major cardiovascular markets and enhances our ability to convert pipeline opportunities faster, while ensuring successful onboarding and long-term retention.

On the clinical front, we are building a robust and increasingly differentiated evidence base. The submission of our heart failure data to a leading cardiology journal, alongside newly published clinical studies and ongoing health economics work, strengthens our positioning with clinicians, regulators and payers. These initiatives are critical in supporting reimbursement pathways and accelerating broader adoption.

Looking ahead, the potential progression of EchoSolv HF through the FDA represents a significant near-term catalyst. Entry into the heart failure market materially expands our addressable opportunity and provides a natural upsell pathway across our existing customer base. Combined with our growing pipeline of additional indications and progression of potential strategic partnerships, this positions EchoSolv as a multi-module platform embedded within the cardiology workflow, capable of driving increasing utilisation and revenue per site over time.

Overall, we believe Echo IQ is well positioned at the intersection of commercial traction, clinical validation and product expansion. With strong momentum across each of these areas, alongside a robust cash balance, we are focused on converting our pipeline into revenue, progressing key regulatory milestones and continuing to scale the platform to deliver long-term, sustainable growth for shareholders."

Operational update:

Agreement with Mayo Clinic in preparation for potential FDA clearance of EchoSolv HF:

Echo IQ expanded its agreement with the the Mayo Foundation for Medical Education and Research ("Mayo"), a legal, non-profit entity of the Mayo Clinic, a top-ranked US hospital to resell and distribute the Company's heart failure clinical decision support solution ("EchoSolv HF") following clearance from the US Food & Drug Administration ("FDA").

Under the amended agreement, EchoSolv HF will be made available through the Mayo Clinic Platform ("MCP") – Solutions Studio Program to Mayo Clinic Hospitals, the Mayo Clinic Health System Network and third-party hospitals participating in the MCP ecosystem, following receipt of FDA clearance.

The updated terms enhance the commercial alignment between the parties and support the planned deployment of EchoSolv HF across the Mayo Clinic Platform. While the original agreement provided Mayo with rights to distribute the solution within its network post-clearance, the revised structure introduces a more balanced economic framework and includes an automatic three-year extension beyond the initial term, providing a potential six-year pathway for commercial collaboration.

Following receipt of FDA clearance, Echo IQ will be positioned to deploy EchoSolv HF via the Mayo Clinic Platform, providing access to a high-volume clinical network and an established distribution channel. This milestone is expected to facilitate the transition from clinical validation to commercial deployment, supporting revenue generation while enabling broader adoption across the Mayo ecosystem and additional participating hospital networks.

EchoSolv AS deployed into the Mount Sinai Health System:

Subsequent to the end of the period, the Company deployed EchoSolv AS with the Mount Sinai Health System in New York, USA. Mount Sinai Health System comprises seven hospitals, over 400 outpatient practices and a globally recognised medical school, the Icahn School of Medicine at Mount Sinai. Specifically, Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital is ranked first in New York and second in the nation for Cardiology, Heart & Vascular Surgery via U.S. News & World Report's 2025–26 Best Hospitals rankings.

The Mount Sinai Health System services millions of patient interactions per annum, encompasses over 3,760 beds across campuses, and is consistently ranked among the top hospitals in the US across multiple specialties, including cardiology and heart surgery. Its scale, research pedigree and clinical leadership position it as a high-volume, high-complexity healthcare network at the forefront of adopting advanced digital health and AI-enabled technologies, including EchoSolv AS.

The deployment represents a meaningful commercial milestone for Echo IQ, reflecting continued growth as healthcare providers and cardiology practices increasingly adopt AI solutions that integrate seamlessly into existing clinical workflows. Collaboration with a leading medical system supports the Company's strategy of expanding EchoSolv AS across prominent cardiovascular institutions, while also strengthening commercial traction and creating opportunities for future research and product development.

EchoSolv AS deployment pipeline strengthening:

Echo IQ continues to demonstrate strong commercial progress across the US, with EchoSolv gaining traction across a broad and expanding network of leading healthcare institutions. During the quarter, the Company has built a robust multi-stage pipeline of over 50 active accounts, across seven commercial stages. This reflects the depth and scalability of the Company's engagement with top-tier US hospital systems.

Presently, Echo IQ is advancing ~23 accounts in qualification and a further 16 in needs analysis, which provides a substantial base for near-term conversion. Importantly, the Company has progressed multiple institutions into advanced stages including eight in value proposition alignment, three with active decision makers, an additional

two with proposals in hand and three under active final contract negotiations. Early commercial success has been underpinned by three closed-won contracts, providing strong third-party validation.

This growing pipeline is underpinned by engagement with a broad cross-section of leading US health systems and academic medical centres, including multiple high-volume and nationally recognised institutions. These engagements reinforce Echo IQ's positioning within large-scale echocardiography networks and support a targeted "land-and-expand" strategy, whereby initial deployments act as a gateway to broader integration across hospital systems and affiliated networks.

From a market development perspective, Echo IQ has identified an additional 250+ high-volume echocardiography centres across the US, representing a significant addressable opportunity. Commercial activity is now active across 4 of 7 priority regions, with structured sales targets delivering 18–25 engagements per representative, highlighting a disciplined and repeatable go-to-market model.

Importantly, the Company is targeting high-volume imaging centres with significant annual study throughput, many of which process tens of thousands to over 100,000 echocardiograms per year. This focus on high-throughput sites maximises revenue potential per deployment while accelerating data scale, further strengthening EchoSolv AS's clinical utility and commercial value proposition.

Collectively, these metrics highlight a rapidly scaling US commercial footprint, with a clear strategy to secure early mover advantage across leading hospital systems. As healthcare providers increasingly prioritise efficiency, early disease detection and AI-enabled workflows, Echo IQ is well positioned to capture a meaningful share of this expanding market through continued pipeline conversion and network expansion.

EchoSolv AS usage accelerating across the US with ~130% QoQ growth:

The Company continues to demonstrate strong and accelerating real-world utilisation of EchoSolv AS in the US. This is underpinned by the total number of echocardiograms processed increasing from 3,992 in Q4 CY25 to 9,220 in Q1 CY26, representing ~131% quarter-on-quarter growth. This step-change reflects both expanding deployment across sites and increasing integration into routine clinical workflows.

Monthly momentum remains strong, with 3,473 echocardiograms processed in March CY26 alone, highlighting a sustained upward trajectory in platform usage as adoption deepens. Importantly, utilisation is being driven by high-throughput environments, with flagship deployment site, Beth Israel Deaconess Medical Center ('Beth Israel' or 'BIDMC'), a leading Harvard Medical Teaching Hospital in Boston, Massachusetts, operating at full capacity across both health economic research and clinical utility applications, reinforcing the platform's ability to perform at scale within leading institutions.

The increasing concentration of studies within major centres, combined with broadening participation across additional sites, underscores EchoSolv AS's growing clinical relevance and operational scalability. This rapid growth in processed volumes provides a clear leading indicator of commercial traction, supporting a transition toward recurring, usage-based revenue streams while strengthening the Company's data asset and long-term competitive positioning.

Key sales and implementation appointments to accelerate US commercial rollout:

To support the continued uptake of EchoSolv technologies across the US, Echo IQ continued to build a high-calibre, regionally aligned US commercial and implementation team during the period.

Additional appointments have followed a stringent recruitment process, under the leadership of US Head of Commercial, Mr Nick Lubbers. Mr Lubbers brings over 15 years of cardiovascular commercial experience across

Boston Scientific, HeartFlow and Tempus, with a proven track record of scaling healthcare focused software platforms through FDA clearance and reimbursement pathways.

The Company has now established a four-region US sales footprint, complemented by dedicated implementation capability to support onboarding and retention:

- **John Croft MBA, RN (Northeast Region)** – 20+ years of cardiovascular healthcare experience, including 15 years in digital cardiovascular solutions. Former top-performing sales director at American multinational medical devices and healthcare company Abbot Laboratories, with a track record in commercial execution.

- **David Christante (Mid-Atlantic Region)** – 20 years of cardiovascular commercialisation experience across Software-as-a Medical-Device (SaMD) and invasive cardiac technologies, with senior roles at HeartFlow and Boston Scientific and deep expertise navigating hospital procurement pathways.

- **JP Bryan (Southeast Region)** – 15 years of cardiovascular experience via Medtronic and Bristol-Myers Squibb, focused on structural heart disease and driving adoption across both device and pharmaceutical channels.

- **Melissa Lode (West Coast Region, commencing 1 May)** – highly accomplished medical device sales leader with 20+ years' experience across vascular, coronary, peripheral and interventional therapies. Brings a strong track record of territory expansion, KOL development and new technology launches, including recent roles at Teleflex, Endologix and Inari Medical. Melissa has consistently delivered new account wins across competitive hospital systems and brings immediate credibility and clinical depth in the strategically important West Coast market.

In parallel, Echo IQ has strengthened its post-sales capability with the appointment of:

- **Divya Patel (Implementation Specialist – West Coast, commencing 1 May)** – experienced implementation and project management professional with a background in leading EMR/EHR deployments and complex healthcare IT integrations, including at major US hospital systems. Divya will support new account onboarding, drive successful integration within the first 90 days and act as a key interface between customers and the Company's product development team to optimise user experience and workflow integration.

Collectively, these appointments materially enhance Echo IQ's commercial capability, spanning sales execution, clinical engagement, implementation and customer success. The expanded team provides dedicated coverage across all major US cardiovascular regions and establishes the operational infrastructure required to convert the Company's growing pipeline into revenue, while supporting scalable, repeatable deployment of EchoSolv AS across hospital networks.

Commercial readiness strengthened through global IP and brand protection:

Echo IQ has materially advanced its commercial readiness through expansion of its intellectual property and brand portfolio. During the quarter, the Company filed 10 new patents across key global jurisdictions, including the US, Europe, Australia and major Asia-Pacific and Middle Eastern markets. This broad geographic coverage supports future international commercialisation and strengthens protection of the Company's core AI and workflow technologies. In parallel, Echo IQ filed four new trademarks across the US and Australia, including EchoIQ and EchoSolv amongst others, further reinforcing brand ownership and market positioning.

Collectively, these initiatives enhance the Company's defensibility, support scalable market entry across multiple regions and underpin long-term value creation as Echo IQ progresses toward broader commercial deployment.

Beth Israel Health Economics study:

Echo IQ has actively progressed real-world evidence generation to further support EchoSolv AS uptake, with interim analysis completed from a Usability and Health Economics study at EchoSolv AS's flagship deployment site, Beth Israel Deaconess Medical Center.

Beth Israel is a leading academic medical centre focused on advanced clinical technologies and medical education. The institution has 743 licensed beds, manages approximately 37,600 inpatient discharges annually, and supports nearly 50,000 emergency department presentations and over 800,000 outpatient visits each year. It performs around 30,000 echocardiograms annually.

Interim study results demonstrate statistically significant increases in platform utilisation and cardiologist confidence in clinical detection when supported by EchoSolv AS. These data are expected to be submitted as a late-breaking presentation to the American Heart Association (AHA), with full study results anticipated in June CY26. Collectively, this work provides critical health economic evidence to support reimbursement pathways and broader clinical adoption.

Expanding global validation, publications and health economic evidence:

The Company significantly strengthened its clinical position during the period, through ongoing progress across international validation, peer-reviewed publications and health economic evidence generation, supporting both regulatory pathways and commercial rollout of the EchoSolv portfolio.

Echo IQ has continued to build its clinical evidence base through high-impact publication activity. Recently generated data from the Company's heart failure model validation study conducted through the Mayo Clinic Platform validation program (refer ASX announcement: 24 November 2025), has been submitted to *JACC: Heart Failure*, a leading global cardiology journal, under the title *"Echo-based, artificial intelligence algorithm identifies future heart failure cases: A blinded, retrospective clinical trial report"*.

The manuscript is supported by a globally recognised group of academic and clinical investigators across leading institutions. Publication of this data is expected to provide independent validation of EchoSolv HF and support regulatory, reimbursement and commercial engagement.

The submission follows the Company's validation study, which met its primary endpoint. Results from the study demonstrated EchoSolv's ability to generate a sensitivity of 99.5% in identifying patients with heart failure and a specificity of 91.1% in correctly identifying patients without heart failure, exceeding expectations and reinforcing strong diagnostic performance.

Further strengthening the evidence base, a randomised controlled crossover study evaluating cardiologist reporting of severe aortic stenosis with and without AI assistance has been published in *iScience*. This study demonstrates the clinical utility of EchoSolv AS in improving diagnostic accuracy and consistency in real-world settings and will form a key component of the Company's clinical and health economic value proposition in commercial discussions.

EchoSolv platform expansion:

During the period, Echo IQ has continued work towards expanding its EchoSolv platform, with a clear strategy to build a multi-condition, AI-enabled cardiology solution increasing clinical utility, customer integration and recurring revenue per deployment.

A key milestone in this strategy is the advancement of EchoSolv HF, where a formal market clearance application was lodged via the FDA's 510(k) premarket notification pathway during Q4 CY25 (refer ASX announcement: 15

December 2025). Subject to clearance, EchoSolv HF is expected to materially expand the Company's addressable patient population and provide a natural upsell opportunity across its growing base of US hospital customers.

Further, Echo IQ is progressing a pipeline of additional cardiovascular indications, including pulmonary hypertension and hypertrophic cardiomyopathy, with further expansion into mitral regurgitation and cardio-oncology over the medium term. This structured, phased approach enables the Company to leverage its existing clinical datasets, regulatory progress and commercial footprint to efficiently bring new modules to market.

Collectively, this expansion strategy positions EchoSolv as a multi-module platform embedded within the cardiology workflow, capable of addressing a broad spectrum of conditions from a single deployment. As additional indications are brought to market, the Company is expected to benefit from increased utilisation, stronger customer retention and compounding revenue growth, reinforcing its long-term positioning within the rapidly growing AI-driven cardiology market.

Outlook:

The Company remains focused on delivering the following milestones over the coming months:

Near-term priorities:

- Major US hospital group signings: Conversion of flagship accounts to establish enterprise beachheads and support broader network rollouts
- EchoSolv HF FDA clearance: Expected to unlock US commercialisation of heart failure module and expand addressable market
- Strategic partnerships: Continued progression of potential partnerships with health systems, drug development companies and industry participants to accelerate commercial deployment and unlock further distribution and co-development opportunities
- Heart failure reimbursement activation: Potential immediate utilisation post-clearance to support early revenue generation and payer engagement
- EU/UK market entry progression: Advancement of CE Mark submission and regulatory pathways to support international expansion
- Australian regulatory progression: Advance clearance via the Therapeutic Goods Administration (TGA) to support local market opportunities

Medium-term value drivers:

- Additional Tier-1 hospital contracts: Expansion from pilot programs to contracted, multi-site deployments across leading health systems
- Aortic stenosis reimbursement advancement: Progress toward structured reimbursement pathways under evolving US healthcare policy
- System-wide hospital rollouts: Transition from single-site installations to enterprise-wide deployments across hospital networks
- Product pipeline expansion: Continued development of additional indications to further embed EchoSolv as a multi-module clinical platform

Corporate:

The Company's cashflow report for the three-month period ended 31 March 2026 follows this announcement. Cash and cash equivalents at 31 March 2026 were $11.14m (31 December 2025: $13.21m). The Company also expects to receive an R&D Tax Incentive in the coming weeks valued ~0.8m, which provides additional financial flexibility. Collectively, cash and cash equivalents provide adequate capital runway for the Company's strategic priorities, including the commercial rollout of EchoSolv HF in the US, which has the potential to drive considerable near-term revenue.

During the quarter, $162,000 in payments were made to related parties and their associates for director salaries, fees, superannuation and other costs.

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:
Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations
Henry.jordan@sdir.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ
Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and for the purposes of ASX Listing Rule 3.1 and ASX Guidance Note 8. Forward-looking statements are statements that are not historical facts and may include, without limitation, statements regarding Echo IQ's commercial growth strategy, anticipated expansion of EchoSolv AS adoption, development of partnerships with health systems and cardiology practices, expected market adoption of AI-enabled decision support tools, and the potential benefits of EchoSolv AS for clinical decision-making and patient care.

These forward-looking statements reflect the current expectations, assumptions, and beliefs of Echo IQ Limited based on information currently available to the company.

Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Such factors include, but are not limited to:
Regulatory Risks: the ability of Echo IQ to maintain FDA 510(k) clearance for EchoSolv AS, obtain or maintain any additional required regulatory approvals in the United States or other jurisdictions, and achieve reimbursement coverage from government and private payors;
Commercial Risks: the rate at which health systems and cardiology practices adopt EchoSolv AS, the ability of the company to execute on existing commercial agreements including with The Mount Sinai Hospital, performance under and renewal of customer contracts, and the competitive environment for AI-enabled medical software;
Financial Risks: the availability of sufficient funding to execute the company's commercial strategy, the timing and magnitude of revenue generation, and the company's ability to achieve and sustain profitability; and
Operational Risks: the performance and reliability of EchoSolv AS technology in real-world clinical environments, the ability to integrate EchoSolv AS into existing clinical workflows, and broader market acceptance of AI-based decision support tools in cardiology.

The assumptions underlying the forward-looking statements in this release are made as of the date of this release and are subject to change without notice. Echo IQ cautions that the foregoing list of risk factors is not exhaustive. Investors and prospective investors should carefully consider these factors, as well as those disclosed in Echo IQ's periodic filings with the ASX and other public disclosures, before making any investment decision.

Echo IQ undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation, including the ASX Listing Rules and the U.S. securities laws.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Echo IQ Limited

ABN	**Quarter ended ("current quarter")**
48 142 901 353	31 March 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(494)	(1,839)
	(c) advertising and marketing	(118)	(442)
	(d) leased assets	-	-
	(e) staff costs	(1,521)	(4,214)
	(f) administration and corporate costs	(649)	(1,792)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	133	455
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(2,649)**	**(7,832)**
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(8)	(35)
	(d) investments	-	-
	(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(8)**	**(35)**
3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	619	919
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(18)	(30)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**601**	**889**
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	13,212	18,136
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,649)	(7,832)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(8)	(35)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	601	889
4.5	Effect of movement in exchange rates on cash held	(16)	(18)
4.6	**Cash and cash equivalents at end of period**	**11,140**	**11,140**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	4,140	3,212
5.2	Call deposits	7,000	10,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**11,140**	**13,212**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(162)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-
7.5	**Unused financing facilities available at quarter end**		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,649)
8.2	Cash and cash equivalents at quarter end (item 4.6)	11,140
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	11,140
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	4.20
	Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	N/A	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	N/A	
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	N/A	
	Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.	

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 April 2026

Authorised by: The Board

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.